Evidence map›Paper›PMID 38292350›Full record

ArticleResearch and practice in thrombosis and haemostasis2024

Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial.

Thor Ueland, Annika E Michelsen, Anders Aune Tveita, Trine Kåsine, Tuva B Dahl, Ane-Kristine Finbråten, Aleksander R Holten, Ole Henning Skjønsberg, Alexander Mathiessen, Katerina N Henriksen and 6 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04321616 (The), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04321616 phase2 / phase3unknown statusnot on this map

The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients

TypeinterventionalSponsorOslo University HospitalRan2020 to 2020Enrolled700ConditionsSARS-CoV Infection, COVID 19, Acute Respiratory Distress Syndrome ARDSArmsHydroxychloroquine, Remdesivir, (Standard of Care) SoC
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Thor UelandResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Annika E MichelsenResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Anders Aune TveitaDepartment of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.
Trine KåsineInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Tuva B DahlResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Ane-Kristine FinbråtenMedical Department, Lovisenberg Diaconal Hospital, Oslo, Norway.
Aleksander R HoltenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ole Henning SkjønsbergInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Alexander MathiessenDepartment of Medicine, Diakonhjemmet Hospital, Oslo, Norway.
Katerina N HenriksenDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
Marius TrøseidResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Trond Mogens AaløkkenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Bente HalvorsenResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Anne Ma Dyrhol-RiiseInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Andreas Barratt-DueDivision of Laboratory Medicine, Department of Immunology, Oslo University Hospital, Oslo, Norway.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Oslo University Hospital · NODiakonhjemmet Hospital · NOLovisenberg Diakonale Høgskole · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several studies have examined parameters of increased thrombogenicity in COVID-19, but studies examining their association with long-term outcome and potential effects of antiviral agents in hospitalized patients with COVID-19 are scarce. Objectives: To evaluate plasma levels of hemostatic proteins during hospitalization in relation to disease severity, treatment modalities, and persistent pulmonary pathology after 3 months. Methods: In 165 patients with COVID-19 recruited into the NOR-Solidarity trial (NCT04321616) and randomized to treatment with hydroxychloroquine, remdesivir, or standard of care, we analyzed plasma levels of hemostatic proteins during the first 10 days of hospitalization ( Results: Our main findings were as follows: (i) tissue plasminogen activator (tPA) and tissue factor pathway inhibitor (TFPI) were increased in patients with severe disease (ie, the combined endpoint of respiratory failure [Po Conclusion: TFPI and tPA are associated with severe disease in hospitalized patients with COVID-19. For TFPI, high levels measured during the first 10 days of hospitalization were also associated with persistent pulmonary pathology even 3 months after hospital admittance.

Indexed as

COVID-19hospitalizationremdesivirtissue factor pathway inhibitortissue plasminogen activator

Identifiers

PMID38292350
PMCPMC10825546
OpenAlexW4389410231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.